INDICATIONS AND USAGE
Minocycline hydrochloride tablets are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms:
Rocky
Mountain spotted fever, typhus fever and the typhus group, Q fever,
rickettsialpox and tick fevers caused by Rickettsiae.
Respiratory
tract infections caused by Mycoplasma pneumoniae.
Lymphogranuloma
venereum caused by Chlamydia trachomatis.
Psittacosis
(Ornithosis) due to Chlamydia psittaci.
Trachoma
caused by Chlamydia trachomatis, although the infectious agent is
not always eliminated, as judged by immunofluorescence.
Inclusion
conjunctivitis caused by Chlamydia trachomatis.
Nongonococcal
urethritis, endocervical, or rectal infections in adults caused by Ureaplasma
urealyticum or Chlamydia trachomatis.
Relapsing
fever due to Borrelia recurrentis.
Chancroid
caused by Haemophilus ducreyi
Plague
due to Yersinia pestis.
Tularemia
due to Francisella tularensis.
Cholera
caused by Vibrio cholerae.
Campylobacter
fetus infections caused by Campylobacter fetus.
Brucellosis
due to Brucella species (in conjunction with streptomycin).
Bartonellosis
due to Bartonella bacilliformis.
Granuloma
inguinale caused by Calymmatobacterium granulomatis.
Minocycline is indicated for treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug:
Escherichia
coli.
Enterobacter
aerogenes.
Shigella species.
Acinetobacter species.
Respiratory
tract infections caused by Haemophilus influenzae.
Respiratory
tract and urinary tract infections caused by Klebsiella species.
Minocycline hydrochloride tablets are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug:
Upper
respiratory tract infections caused by Streptococcus pneumoniae
Skin
and skin structure infections caused by Staphylococcus aureus.
(Note: Minocycline is not the drug of choice in the treatment of any type
of staphylococcal infection.)
When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections:
Uncomplicated
urethritis in men due to Neisseria gonorrhoeae and for the
treatment of other gonococcal infections
Infections
in women caused by Neisseria gonorrhoeae.
Syphilis
caused by Treponema pallidum subspecies pallidum.
Yaws
caused by Treponema pallidum subspecies pertenue.
Listeriosis
due to Listeria monocytogenes.
Anthrax
due to Bacillus anthracis.
Vincent's
infection caused by Fusobacterium fusiforme.
Actinomycosis
caused by Actinomyces israelii.
Infections
caused by Clostridium species.
In acute intestinal amebiasis, minocycline may be a useful adjunct to amebicides.
In severe acne, minocycline may be useful adjunctive therapy.
Oral minocycline is indicated in the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate the meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high.
Oral minocycline is not indicated for the treatment of meningococcal infection.
Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of, minocycline hydrochloride tablets and other antibacterial drugs, minocycline hydrochloride tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.